|本期目录/Table of Contents|

[1]肖 慧,徐维国,范小兵,等.血清IL-34、SP-D、CXCL17在甲型流感病毒性肺炎患者中表达及临床意义[J].中华肺部疾病杂志,2023,(03):349-351.[doi:10.3877/cma.j.issn.1674-6902.2023.03.010 ]
点击复制

血清IL-34、SP-D、CXCL17在甲型流感病毒性肺炎患者中表达及临床意义(PDF)

《中华肺部疾病杂志》[ISSN:1006-6977/CN:61-1281/TN]

卷:
期数:
2023年03期
页码:
349-351
栏目:
临床研究
出版日期:
2023-06-20

文章信息/Info

Title:
-
作者:
肖 慧; 徐维国; 范小兵; 李厚衡
621000 绵阳,电子科技大学医学院附属绵阳医院·绵阳市中心医院呼吸与危重症医学科
Author(s):
-
关键词:
甲型流感病毒性肺炎;  白介素-34;  肺表面活性蛋白;  CXC趋化因子配体17
Keywords:
-
分类号:
R563
DOI:
10.3877/cma.j.issn.1674-6902.2023.03.010
摘要:
目的 分析甲型流感病毒性肺炎患者血清白介素-34(IL-34)、肺表面活性蛋白(SP-D)、CXC趋化因子配体17(CXCL17)的表达及临床意义。方法 选取2017年1月至2020年12月我院收治的甲型流感病毒性肺炎患者108例,比较轻症、重症及不同预后血清IL-34、SP-D、CXCL17水平。分析预后危险因素。结果 患者血清IL-34(26.17±5.59)pg/ml、SP-D(38.23±9.10)ng/ml、CXCL 17(10.43±2.71)ng/ml。重症者血清IL-34(38.43±10.72 vs. 16.29±3.88)pg/ml、SP-D(53.95±14.83 vs. 25.57±6.09)ng/ml、CXCL17(15.53±4.08 vs. 6.32±1.81)ng/ml高于轻度者(P<0.05)。Pearson相关性分析血清IL-34、SP-D、CXCL17分别与SOFA 评分、APACHEⅡ评分呈正相关(P<0.05)。18例死亡SOFA评分、APACHEⅡ评分及血清IL-34、SP-D、CXCL17高于生存者(P<0.05)。多因素Logistic回归分析血清IL-34、SP-D、CXCL17升高是甲型流感病毒性肺炎患者死亡预后的危险因素(P<0.05)。ROC曲线显示IL-34、SP-D、CXCL17及联合检测甲型流感病毒性肺炎患者预后的AUC分别为0.812(95%CI:0.703～0.917,P<0.001)、0.792(95%CI:0.680～0.905,P<0.001)、0.804(95%CI:0.696～0.912,P<0.001)、0.905(95%CI:0.829～0.980,P<0.001)。结论 甲型流感病毒性肺炎患者血清IL-34、SP-D、CXCL17上升,与病情及预后相关,联合检测判断患者预后具有临床意义。
Abstract:
-

参考文献/References:

1 Karunarathna HMTK, Perera RAPM, Fang VJ, et al. Serum anti-neuraminidase antibody responses in human influenza A(H1N1)pdm09 virus infections[J]. Emerg Microbes Infect, 2019, 8(1): 404-412.
2 谢 云, 王瑞兰. 流感季节重症肺炎救治观念[J/CD]. 中华肺部疾病杂志(电子版), 2018, 11(3): 261-264.
3 Baghdadi M, Ishikawa K, Nakanishi S, et al. A role for IL-34 in osteolytic disease of multiple myeloma[J]. Blood Adv, 2019, 3(4): 541-551.
4 梁海梅, 欧宗兴, 齐见旭, 等. 慢性阻塞性肺疾病急性加重期患者血清IL-34水平的变化及临床意义分析[J]. 临床肺科杂志, 2021, 26(9): 1431-1433.
5 Saleh NY, Ibrahem RAL, Saleh AAH, et al. Surfactant protein D: a predictor for severity of community-acquired pneumonia in children[J]. Pediatr Res, 2022, 91(3): 665-671.
6 刘祖平. CXCL17在肿瘤中表达意义及功能的研究进展[J]. 西南医科大学学报, 2018, 41(5): 462-466.
7 国家卫生和计划生育委员会, 国家中医药管理局. 流行性感冒诊疗方案(2018年版)[J]. 中国感染控制杂志, 2018, 17(2): 181-184.
8 樊高薇, 薛敬东, 李警卓. 基于JAK/STAT信号通路探讨连花清瘟颗粒对甲型H1N1流感病毒性肺炎小鼠肺组织的保护作用及机制[J]. 检验医学与临床, 2022, 19(9): 1153-1157, 1162.
9 Behillil S, May F, Fourati S, et al. Oseltamivir resistance in severe influenza A(H1N1)pdm09 pneumonia and acute respiratory distress syndrome: A french multicenter observational cohort study[J]. Clin Infect Dis, 2020, 71(4): 1089-1091.
10 Eldaboosy S, Almoosa Z, Saad M, et al. Comparison between physiological scores SIPF, CURB-65, and APACHE Ⅱ as predictors of prognosis and mortality in hospitalized patients with COVID-19 pneumonia: A multicenter study, Saudi Arabia[J]. Infect Drug Resist, 2022, 15: 7619-7630.
11 HoSgün D, Aydemir S. Factors affecting 90-day mortality in community and hospital acquired pneumonia patients with or without acute kidney injury[J]. Afr Health Sci, 2022, 22(3): 567-577.
12 Dépret F, Riaud C, Rouaux J, et al. Characteristics and prognosis of Herpesviridae-related pneumonia in critically ill burn patients[J]. Burns, 2022, 48(5): 1155-1165.
13 Park HE, Oh H, Baek JH. Interleukin-34-regulated T-cell responses in rheumatoid arthritis[J]. Front Med(Lausanne), 2022, 9: 1078350.
14 Monteleone G, Franzè E, Troncone E, et al. Interleukin-34 mediates cross-talk between stromal cells and immune cells in the Gut[J]. Front Immunol, 2022, 13: 873332.
15 Alshaebi F, Safi M, Algabri YA, et al. Interleukin-34 and immune checkpoint inhibitors: Unified weapons against cancer[J]. Front Oncol, 2023, 13: 1099696.
16 Udomsinprasert W, Panon K, Preechanukul S, et al. Diagnostic value of interleukin-34 as a novel biomarker for severity of knee osteoarthritis[J]. Cartilage, 2021, 13(2_suppl): 1174S-1184S.
17 张 津, 杨敬平, 徐喜媛, 等. 以ALI为表现的脓毒症患者外周血PBMC TLR4mRNA及IL-34、IL-36的表达[J]. 临床肺科杂志, 2016, 21(7): 1172-1176.
18 Xu B, Lin X, Gong Y, et al. Interleukin-34: an important modifier in the pathogenesis of influenza pneumonia[J]. Crit Care, 2021, 25(1): 274.
19 Abdel-Razek O, Audlin J, Poe DS, et al. Surfactant proteins and innate immunity of otitis media[J]. Innate Immun, 2022, 28(7-8): 213-223.
20 Watson A, Madsen J, Clark HW. SP-A and SP-D: Dual functioning immune molecules with antiviral and immunomodulatory properties[J]. Front Immunol, 2021, 11: 622598.
21 Saleh NY, Ibrahem RAL, Saleh AAH, et al. Surfactant protein D: a predictor for severity of community-acquired pneumonia in children[J]. Pediatr Res, 2022, 91(3): 665-671.
22 Chakrabarti A, Nguyen A, Newhams MM, et al. Surfactant protein D is a biomarker of influenza-related pediatric lung injury[J]. Pediatr Pulmonol, 2022, 57(2): 519-528.
23 Choreño-Parra JA, Jiménez-Álvarez LA, Ramírez-Martínez G, et al. Expression of surfactant protein D distinguishes severe pandemic influenza A(H1N1)from coronavirus disease 2019[J]. J Infect Dis, 2021, 224(1): 21-30.
24 Xiao S, Xie W, Zhou L. Mucosal chemokine CXCL17: What is known and not known[J]. Scand J Immunol, 2021, 93(2): e12965.
25 Sun C, Shen H, Cai H, et al. Intestinal guard: Human CXCL17 modulates protective response against mycotoxins and CXCL17-mimetic peptides development[J]. Biochem Pharmacol, 2021, 188: 114586.
26 郭雅洁, 欧周罗, 邵志敏. 新型趋化因子CXCL17[J]. 生命的化学, 2013, 33(6): 657-661.
27 José A, Shyamala T, Joaquín Z, et al. The protective and pathogenic roles of CXCL17 in human health and disease: Potential in respiratory medicine[J]. Cytokine Growth Factor Rev, 2020, 53: 53-62.
28 Zhang K, Liang Y, Feng Y, et al. Decreased epithelial and sputum miR-221-3p associates with airway eosinophilic inflammation and CXCL17 expression in asthma[J]. Am J Physiol Lung Cell Mol Physiol, 2018, 315(2): L253-L264.
29 Ardain A,Domingo GR, Das S, et al. Group 3 innate lymphoid cells mediate early protective immunity against tuberculosis[J]. Nature, 2019, 570(7762): 528-532.
30 Jose A, Luis A, Gustavo R, et al. CXCL17 is a specific diagnostic biomarker for severe pandemic influenza A(H1N1)that predicts poor clinical outcome[J]. Front Immunol, 2021, 12: 633297.

备注/Memo

备注/Memo:
基金项目: 北京白求恩公益基金会资助项目(SCZ057CS)
通信作者: 徐维国, Email: xwg522630@163.com
更新日期/Last Update: 2023-06-20